Edwin Posadas discusses RTOG 3506 (STEEL), a phase II trial adding enzalutamide to salvage radiation plus two years of androgen deprivation therapy in extremely high-risk post-pro ...

Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...

Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

Schweitzer, K. Study points to biology-not just behavior- in the mortality gap between males and females. JAMA, published online, February 20, 2026 Anderer, S. Cardiovascular disease risk climbs ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer session and a Society of Urologic Oncology (SUO) lecture ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in upper tract urothelial carcinoma session and a presentation by Dr. Savio Domenico Pandolfo discussing the ...

The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...

This is the largest study exploring how we should treat people who present at A&E with blood in their urine. It’s a common problem affecting thousands of people around the world, and these patients ...